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G-protein-coupled receptors (GPCRs) constitute a large family of cell surface
receptors that are involved in a wide range of physiological and pathological
processes, and are targets for many therapeutic interventions. However,
genetic models in the rat, one of the most widely used model organisms in
physiological and pharmacological research, are largely lacking. Here, we
applied N-ethyl-N-nitrosourea (ENU)-driven target-selected mutagenesis to
generate an in vivo GPCR mutant collection in the rat. A pre-selected panel
of 250 human GPCR homologs was screened for mutations in 813 rats,
resulting in the identification of 131 non-synonymous mutations. From
these, seven novel potential rat gene knockouts were established as well as
45 lines carrying missense mutations in various genes associated with or
involved in human diseases. We provide extensive in silico modeling results of
the missense mutations and show experimental data, suggesting loss-of-
function phenotypes for several models, including Mc4r and Lpar1. Taken
together, the approach used resulted not only in a set of novel gene
knockouts, but also in allelic series of more subtle amino acid variants, similar
as commonly observed in human disease. The mutants presented here may
greatly benefit studies to understand specific GPCR function and support the
development of novel therapeutic strategies.
The Pharmacogenomics Journal (2011) 11, 326–336; doi:10.1038/tpj.2010.44;
published online 8 June 2010
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Introduction
Treatment of animals with a mutagenic compound that introduces random
mutations in the germ line is a very fast and efficient method for introducing a
wide range of mutations in large sets of genes in vivo. In rodents, ENU has been
shown to be the most potent chemical germ line mutagen.
1 ENU treatment of
male animals causes adducts in the DNA of spermatogonial stem cells, which
after several rounds of cell division, result in random point mutations and
mutagenized sperm.
2 F1 animals derived from outcrosses with wild-type females
carry random heterozygous ENU-induced mutations in their genome. Subse-
quently, the DNA of these animals can be screened by a variety of techniques for
the presence of mutations in pre-selected genes of interest,
3,4 with the goal to
identify animals that carry induced variants that affect normal protein function,
for example, by the introduction of a premature stop or by affecting functionally
important residues.
The laboratory rat Rattus norvegicus is one of the most used model organisms in
biomedical research and has been the preferred model for studying human
physiology and pathology.
5 As a highly diverged mammalian model (B60
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mouse
6), the rat is highly complementary to the mouse,
enabling phenotypic comparison of gene knockouts in both
mammals to better understand the specific gene function in
human biology. In addition, in specific cases the rat can
have advantages in studying mammalian physiology and
biology due to its relative large body size and the availability
of well-established behavioral and neurological assays.
7
Although most rat knockout models have thus far been
generated through ENU-driven approaches, only recently
alternative technologies emerged. Transposon-tagged muta-
genesis,
8 zinc-finger nuclease-mediated knockout genera-
tion
9 and the isolation of pluripotent ES cells that
potentially can be used for gene targeting
10,11 now provide
a range of possibilities for manipulating the rat genome and
promises to boost the use of the rat as a versatile genetic
model system. ENU-driven target-selected mutagenesis has
specific characteristics that make it an attractive technology
that is complementary to the other approaches.
12 First, it is a
relatively simple technology without any cell or oocyte
manipulation steps. Second, it can easily be scaled up for
high throughput and is a relatively cheap method, especially
in terms of the number of animals used per knockout (in
this paper B100 rats). Third, it offers the possibility to
identify (allelic series of) more subtle variation because of
amino acid changes that result in hyper- and hypomorphic
alleles.
3,4 One of the major disadvantages of the ENU-based
approach was its relative inefficiency. However, recently we
increased the efficiency by about 2.5-fold by taking
advantage of DNA mismatch repair (MMR)-deficiency in
the MSH6 knockout rat,
13,14 a system known to be involved
in repairing ENU-induced lesions in the genome.
15 Further
efficiency improvements can be expected by implementing
next-generation sequencing technology for mutation dis-
covery. Another drawback of the method is that mutation
generation is random and that only the discovery is done in
a targeted fashion. In other words, generation of knockouts
is relatively efficient, but obtaining a knockout for a specific
gene is still challenging. However, ENU-driven target-
selected mutagenesis is a versatile technology for the
systematic generation of large catalogs of knockouts and
allelic variants of gene families or eventually all protein-
coding genes. The latter approach in combination with
efficient cryopreservation and rederivation protocols would
generate a unique genome-wide resource for knockouts as
well as mutant alleles reflecting human genetic variation.
Here, we applied the improved ENU-driven target-selected
mutagenesis method for generating a unique resource of in
vivo GPCR mutant rat models consisting of both knockouts
as well as (allelic series of) missense mutations. G-protein-
coupled receptors (GPCRs) are 7 transmembrane (TM)
receptors, which regulate many cellular processes, including
the senses of taste, smell, and vision and control a myriad of
intracellular signaling systems in response to external
stimuli. Importantly, many diseases are linked to GPCRs
and they represent by far the largest class of targets for
current drugs as well as for the development of novel small-
molecule medicines.
16 Moreover, because of their role in the
regulation of cellular function they are arguably one of the
best-studied classes of proteins, although for many GPCRs
their ligand as well as biological function remains to be
elucidated. Furthermore, genetically altered GPCR animal
models are scarce, especially in non-murine species, The use
of a random mutagenesis approach for the generation of
GPCR mutants is in principle very well suited for under-
standing the in vivo receptor function as new insights can be
obtained by completely knocking out specific receptors, but
also by changing functionally important residues, for
example, involved in ligand binding or second messenger
signal transduction. Importantly, the high structural con-
servation between the different GPCRs allows for confident
prediction of possible effects of amino acids changes. We
systematically applied the ENU-driven target-selected muta-
genesis approach to a set of about 250 rat GPCRs that have
clear orthologs to human GPCRs. In total, we identified 131
non-synonymous mutations in 99 different GPCRs, includ-
ing 7 novel potential knockout alleles and 45 missense
mutants that were predicted to affect specific GPCR function
or stability of folding of the protein. Characterization of
selected models shows that ENU target-selected mutagenesis
is a powerful and efficient approach for in vivo functional
studies on G-protein-coupled receptors.
Materials and methods
Animals and ENU target-selected mutagenesis protocol
All experiments were approved by the Animal Care Com-
mittee of the Royal Dutch Academy of Sciences according to
the Dutch legal ethical guidelines. Experiments were
designed to minimize the number of required animals and
their suffering. ENU treatment of male MSH6 knockout rats
(Msh6
1Hubr) was done as described.
14 Animals were housed
under standard conditions in groups of two to three per cage
per gender under controlled experimental conditions (12–h
light/dark cycle, 21±11C, 60% relative humidity, food
and water ad libitum). Genes of interest were screened using
PCR amplification followed by capillary sequencing as
described.
14
Project management and primer design using LIMSTILL
The resequencing experiments were designed and managed
using LIMSTILL, LIMS for Induced Mutations by Sequencing
and TILLing (V Guryev, E Cuppen, unpublished). This web-
based publicly accessible information system (http://lim-
still.niob.knaw.nl) was used to generate projects and
visualize gene structures based on Ensembl genome data,
the design of PCR primers, and entry, archiving and primary
interpretation of mutations. The primer design application
within LIMSTILL is Primer3-based
17 and parameters are set
to design primers with an optimal melting temperature of
581C. The sequences of the primers used in this project are
available upon request.
Mutant effect prediction
Mutation data were retrieved from the GPCRDB,
18 which
contains a large number of mutants that were obtained from
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19 and mutations that were automati-
cally extracted from literature by the software package
MuTeXt.
20 The mutants from the GPCRDB that were used
in the analyses include mutants at the same position and in
the same receptor as the novel mutants as well as mutants at
corresponding residue positions in related proteins. Each
mutant in the GPCRDB contains references to literature. The
literature describing these mutations was manually checked
for relevance and descriptions of the mutant. If the mutation
in the mutated receptor or highly homologous receptor has
already been described in literature and the results of the
experiments are interpreted correctly, we can be reasonably
certain of the effects of the mutation on protein function.
When no good mutation data was available residue
conservation in the multiple sequence alignments was
analyzed. By analyzing residue conservation in multiple
sequence alignments we can estimate if the mutant residue
is likely to be tolerated. If residue conservation at the
position of the mutant is high it is very likely that the
mutant has a detrimental effect. If there is little variability
the properties of the residues, that is, charge or aromaticity,
are likely to be important. When there is a lot of variability
the effect of the mutant is probably largely determined by
size constraints if the residue is located on the inside of the
protein, or effects due to changes in hydrophobicity if the
residue is located at the outside of the protein. Alignments
of the primary protein family as well as the superfamily were
used. The alignments were obtained from the GPCRDB.
Mutants are best studied in the context of a receptor
structure, where the local environment of the mutated
residue can shed light on its function and tolerated
substitutions. For this, we used the homology models of
the receptors that were mutated. Homology models of the
receptors were built automatically using in-house software.
The recently resolved crystal structures
21–23 were used as
templates from which the software automatically detected
the best for each model. The alignments of the GPCRDB
were used to align the model with the template.
The effects of the mutations were estimated by manually
combining and interpreting the results of the mutant literature
searches and the analyses of alignments and homology models
and was performed by experts in this field of research.
In vitro fusion protein expression studies
Wild-type and mutant receptors were N-terminally haemag-
glutinin (HA) tagged and cloned into the expression vector
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The receptor
fusion proteins were expressed in COS-7 cells, which were
seeded on a coverslip, and 24h after transfection the cells
were placed on ice and incubated with DMEM-buffered
HEPES containing 0.2% fatty acid-free bovine serum albu-
min (DHB) for 15min. Subsequently, the cells were incu-
bated for 1h with a polyclonal rabbit anti-HA (Abcam,
Cambrigde, UK) on ice in DHB at a 1:250 dilution. The cells
were methanol-fixed and washed thoroughly with PBS and
incubated for 1h in blocking buffer (1% BSA in 0.1% PBS-
Tween) at room temperature. The cells were washed three
times with PBS and incubated for 1h with a secondary anti-
rabbit antibody conjugated with FITC (Abcam) at room
temperature in the dark. After three times washing with PBS
the coverslips were mounted using Vectashield with DAPI
(Brunschwig chemie, Amsterdam, Netherlands) and analyzed
using confocal microscopy. For western blotting COS-7 cells
were lysed 24h after transfection and the proteins were
separated on a SDS gel (10% acrylamide gradient, Bio-Rad,
Hercules, CA, USA) and transferred to a nitrocellulose mem-
brane. The membrane was incubated for 1h at room
temperature with either a 1:4000, 1:500 or 1:2000 dilution of
respectively a polyclonal rabbit anti-HA antibody (Abcam), a
polyclonal rabbit anti-human EDG2 (LPAR1) antibody (Abcam
Inc) or a polyclonal rabbit anti-actin antibody (Sigma Aldrich,
St Louis, MO, USA) in blocking buffer followed by an incu-
bation for 1h with peroxidase-conjugated, anti-rabbit IgG
diluted 1:2000 in blocking buffer at room temperature. Protein
bands were detected by using the enhanced chemilumines-
cence detection method (ECL, Amersham Biosciences,
Buckinghamshire, UK).
Results
ENU target-selected mutagenesis setup
The target rat GPCR genes for mutation screening were
selected based on one-to-one orthology with human GPCRs
(as defined in Ensembl database), where odorant receptors
were excluded. GPCRs are ideal genes for mutation screening
by PCR-based resequencing in an ENU target-selected muta-
genesis setup because these genes are often encoded by only a
single long exon, which maximizes the information content
per target amplicon. Although the chance of identifying
mutations in splice site residues, which often results in a
knockout allele, is decreased, this is compensated by a higher
number of non-synonymous mutations. The genes of interest
were screened using a nested PCR amplification setup
followed by dideoxy resequencing.
3 Although different
methods for mutation retrieval can be used, like a yeast-based
assay,
4 CEL1-based nuclease cleavage
24 or Mu transposase-
based detection,
25 resequencing is considered to be the golden
standard because it is equally sensitive toward all types of
point mutations and is well suited for scaling and automation.
After a first round of amplicon testing a panel of 486 different
amplicons covering 250 different GPCRs for screening was
established (Supplementary Table 1).
MSH6-deficient males (msh6
 / ) were mutagenized with a
predetermined optimal dose of three weekly treatments of
30mg per kg bodyweight of ENU,
14 which yielded 18 fertile
founders (Table 1). Subsequently, mating the ENU-treated
msh6
 /  males with untreated females generated a mutant
F1 population, harboring random heterozygous ENU-in-
duced mutations. Only F1 animals were screened that were
generated after a full cycle of spermatogenesis (460 days
after mutagenesis) to prevent retrieval of chimeras. Genomic
DNA of the F1 animals was isolated from a tail clip that
was collected at 1–2 weeks of age and screened for the
ENU-induced mutations in the preselected panel of genes-
of-interest. F1 animals carrying interesting candidate mutations
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independent assays. In total, we screened 813 F1 animals,
covering 139Mb of DNA (Table 1) and identified 193 unique
mutations, resulting in a mutation rate of 1 per 720kb,
which is in agreement with the previously described
increased mutation frequency in msh6
 /  rats.
14
ENU-induced mutations
Out of the 193 ENU-induced mutations, 163 are located in
coding sequences and 131 result in non-synonymous
changes in 99 different GPCRs (Supplementary Table 2).
We identified nine mutations that cause the introduction of
a premature stop codon in the open reading frame. These
represent 5.5% of all coding mutations (Table 1) and
corresponds well with the expected percentage of knockout
alleles when considering codon usage in the rat and the
mutation spectrum in an MMR-deficient background,
14 In
all, 122 mutations were identified that cause an amino acid
change (missense). As expected, none of the non-coding
mutations mutated a splicing donor/acceptor site.
In silico analysis of the mutations
To categorize and prioritize the non-synonymous mutations,
the effects of the mutations on protein function was analyzed
in silico by evaluating available experimental mutation data,
analyzing residue conservation patterns in multiple sequence
alignments and studying homology models of the mutated
receptors. As the structure of a protein is directly related to its
function, the best way of estimating the effects of a mutant is
by studying the protein structure itself. Unfortunately, there is
very limited structural data available for GPCRs. However,
based on alignment data and the few experimentally resolved
protein structures,
21–23 it is possible to build structure models
of most class A GPCRs.
T h en i n en o n s e n s em u t a t i o n sthat introduce a premature
stop codon in the open reading frame will result in truncated
versions of the proteins and are most likely to result in
complete functional knockouts of the genes (Figure 1). The
122 missense mutations can be grouped in amino acid changes
Table 1 ENU mutation efficiency













Mutation rate 1 per 720kb
aMSH6-deficient male animals were treated three times weekly with 30mgkg
–1
bodyweight ENU. Founders were considered to be fertile if at least one nest was
produced more than 10 weeks after the last ENU treatment.
bOnly F1 animals were screened that were born at least 10 weeks after the last
ENU treatment.
Figure 1 Systematic in silico analysis of the identified ENU-induced mutations. All mutations were grouped according to their predicted affect on
GPCR function. Mutations that are likely to affect protein function can be further categorized depending on their effect on GPCR function. The
group for which no predictions can be made by lack of structural data were analyzed with PolyPhen
27 and SIFT
28 software.
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will have little or no effect (Supplementary Table 2). For 40
mutations we predicted that they are likely to affect receptor
function and for 23 mutations to have no effect (Figure 1). For
59 mutations no good predictions could be made, which was
largely due to the position of these mutations in loop regions,
where sequence conservation is low and where very little
structural information is available. The damaging mutations
can be further categorized in mutations that affect specific
GPCR functions, like ligand binding, signal transduction, G-
protein activation or protein stability. Eight mutations were
predicted to affect the process of ligand binding, because they
involved a residue located in the putative ligand-binding
pocket (Figures 2a and b). Another six mutations are likely to
affect signal transduction, for example the mutant Prok2
S364I,
w h i c hi n v o l v e sar e s i d u et h a ti sp a r to ft h ei o n i cl o c k( F i g u r e s
2a and c).
26 In all, 13 mutations were identified that are likely
to affect G-protein activation by changing residues involved in
the binding of the G-protein, like the W153R mutation in the
highly conserved (D/E)R(Y/W) motif of Hcrtr2 (Figures 2a and
d). Finally, a total of 13 mutations were identified that are
likely to affect protein stability, for example by changing a
hydrophobic residue that sticks into the lipid bilayer into a
hydrophilic one.
For mutations with unclear predictions we made use of
PolyPhen
27 and SIFT
28 software to predict the effects of the
amino acid changes (Figure 1). Fifteen mutations were
predicted to be damaging by both programs, 20 were
predicted to be damaging by one of the programs and 24
were predicted not to be damaging by either program.
Archiving the mutants
F1 animals carrying interesting mutations were outcrossed
with untreated animals to establish the mutant lines and
generate more heterozygous carriers. Mutants that were
predicted to have no effect on GPCR function were archived
by cryopreserving sperm of male carriers from either the F1
or F2 generation. The resulting resource can be used to
revive these lines by ICSI
25 at a later stage. In a limited
number of cases we were unable to cross F1 animals to the
next generation, partly due to fertility problems, which is
more commonly observed in F1 animals derived from ENU-
mutagenized founders, or as a result of a dominant effect of
the induced mutation. For example, the mutation of an
aspartic acid (D74V) in the second TM domain of Agtr1a,
which is part of the ionic pocket
26 and a highly conserved
residue in GPCR super family, resulted in an extremely high
blood pressure-like phenotype (increased liver, heart and
Figure 2 Illustrations of the mutant structural environments in homology models of the mutated receptors. (a) Schematic overview of a consensus
GPCR with the mutation shown in (b) in red, in orange the ionic pocket
26 and mutated residue in (c) and in yellow the (D/E)R(Y/W) motif and
mutated residue depicted in (d). (b) An example of a mutation that is predicted to affect ligand binding. The mutant H410L in the neuropeptide
receptor NPY5R is located in the putative ligand-binding pocket. The structure of the co-crystallized ligand of the b2-adrenergic receptor is shown in
gray. Although the NPY5R receptor binds a different class of ligands the binding site location is expected to be similar. Substituting the histidine for
leucine is likely to change ligand-binding affinity. (c) The mutant S364I in the prokineticin 2 (PROK2) is located just above the ionic pocket, which is
involved in signal transduction from the ligand-binding site to the G-protein-binding site. A number of structural waters are located in this pocket.
The substitution of the serine for isoleucine is likely to disrupt the ionic pocket due to steric constraints, a major change in hydrophobicity and losso f
interactions with structural waters. (d) The mutant W153R in the hypocretin (orexin) receptor 2 (HCRTR2) is located in the (D/E)R(Y/W) motif, which
is the most conserved part of the GPCR family and involved in receptor activation and subsequent G-protein coupling. The substitution of
trypthophan for arginine will disrupt receptor activation.
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causing sterility and eventually death (data not shown).
Completely in line with these observed in vivo effects, a
similar amino acid change D74N was shown previously to
affect AGTR1A function in vitro in COS cells.
29
The mutants that were successfully crossed to the next
generation were genotyped for carrying the mutation of
interest as well as contra-selected for the mutation in Msh6.
All F1 animals are heterozygous for the latter mutation as
the ENU-mutagenesis was done in msh6
 /  males that
were subsequently outcrossed to wild-type females.
Although no adverse effects are expected in a heterozygous
Msh6 background, in later generations the mutation
could become homozygous and result in the accumulation
of more mutations and cancer.
13 Therefore, we system-
atically selected F2 animals to eliminate this mutation from
the lines.
Table 2 lists the rat mutants that were crossed to next
generations and for which living carriers are available. These
include seven mutant lines with protein truncations and
contain well-studied receptors, like Mc4r, of which muta-
tions in human have been associated with severe forms of
obesity,
30 as well as orphan receptors, like Gpr19 (Table 2).
Furthermore, 45 animals that carry mutations that likely
affect GPCR function were crossed to following generations
to establish a mutant line. These include six mutations that
are predicted to affect ligand binding, six that may affect
signal transduction and nine that may affect G-protein
activation. In addition, 11 mutations that are predicted to
affect protein stability and 13 with unclear effects on GPCR
function or stability, but that were predicted to be damaging
by both PolyPhen
27 and SIFT,
28 were crossed to next
generations.
Functional consequences of ENU-induced mutations
Mutations that result in the introduction of a premature
stop codon most likely represent novel functional gene
knockout models for these genes in the rat, similar as has






34 Six of the nonsense mutants that
were isolated in this screen cause protein truncations within
or before the 7th TM domain and therefore lack the entire C
terminus, including the 8th helix, which is important for
GPCR stability and function. The remaining ENU-induced
premature translational stop was identified in the 8th helix
of MC4R (Mc4r
K314X), four amino acids before the palmi-
toylated cysteine residue (Figure 3a). Most likely, this
mutation results in a complete loss of receptor function,
because the two isoleucines residues, which are located after
the mutated residue (Figure 3a) were shown previously to be
essential for localizing MC4R to the plasma membrane.
35 In
addition, C-terminally truncated versions of another GPCR,
namely the lysophosphatidic receptor LPAR1 also fail to
localize to the plasma membrane,
36 indicating the impor-
tance of the C terminus for correct membrane expression. To
test this hypothesis, we expressed N-terminally HA-tagged
MC4R with and without the ENU-induced mutation in COS
cells. After transfection, intact non-permeabilized cells were
incubated with an antibody against the HA-tag, which can
only bind if the HA-MC4R fusion protein is correctly
incorporated into the plasma membrane. Indeed, HA-tagged
wild-type MC4R was clearly detectable at the plasma
membrane, whereas no mutant receptor could be detected
in the same assay (Figure 3b). To test whether the mutant
form was ever expressed in these cells, we detected the
protein in fixed and permeabilized transfected cells and
showed the presence of approximately equal amounts of
expression of both wild-type and mutant HA-MC4R fusion
proteins (Figure 3c). This shows that Mc4r
K314X is still
expressed in vitro, but fails to localize to the plasma
membrane, which is likely to affect normal receptor
function. In line with these predictions, Mc4r
K314X/K314X rats
display a major increase in body weight as well as in the
amount of peritoneal and subcutaneous fat (Supplementary
Figure 1), which is a comparable phenotype reported for
traditional knockout mouse models
37 suggesting loss of
Mc4r receptor function in this rat mutant.
Obviously, for missense mutations it is more difficult to
robustly predict an affect. However, to confirm the value of
the stringent bioinformatic predictions that we implemen-
ted, a mutation in Lpar1 that results in the change of a
methionine into an arginine in the 8th helix (Figure 4a) and
that was predicted to be deleterious for protein function,
was analyzed. Interestingly, aberrant lysophosphatidic sig-
naling in humans has been associated with carcinogenesis in
humans
38 and specifically LPAR1 knockout mice show




Protein truncation Ccr4, Gpr19, Gpr65, Gpr84, Htr1f, Il8rb, Mc4r
Ligand binding Adra1b, Nmur2, Npy5r, P2ry1, P2ry13, Tacr1
Signal transduction Fzd6, Galr1, Htr4, Il8rb
c, Prokr2, Ptafr,
G-protein activation Edg2, Eltd1
d, Gpr120, Gpr68, Hcrtr2, Lhcgr
d, Mrgprd
d, Sstr2, Sstr5
Protein stability/folding Bdkrb2, Chrm5, Cx3cr1, Fshr, Fzd7, Gnrhr, Gpr4, Gpr85, Mc5r, Mtnr1b, Smo
Unclear effect
e Drd3, Ffar3, Gpr116, Gpr142, Gpr15, Gpr182, Gpr56, Grm5, Htr2a, Lpar4, P2ry4, Xcr1
R137C, Xcr1
R218W
aThese mutant rat lines are crossed out to at least the F2 generation and living carriers are available.
bThe categories are based on expert interpretation of structural information and bioinformatic predictions unless stated differently.
cThis mutation is linked to Il8rb
C307X.
dThese mutations were predicted to result in an increased constitutive activity of the receptors.
eStructural information was not available for these protein domains but bioinformatic analysis by both Polyphen
27 and SIFT
28 software predicted that these mutations are
likely to have damaging consequences.
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39 In
the GPCR class A family the hydrophobicity of the affected
residue is highly conserved and it is analogous to the
phenylalanine of the NPxxY(x)6F motif in Rhodopsin. This
residue sticks into a hydrophobic pocket and contacts
the tyrosine of the same domain, which is important for
the folding of the 8th helix. The amino acid change in our
mutant will disrupt the hydrophobic interactions and
additionally, an arginine is too big to fit in this pocket and
will most probably result in incorrect packing of the 8th
helix (Figure 4b). As a consequence, the environment of
G-protein binding will be disturbed by the mutation in
Lpar1
M318R, because it is thought that this helix interacts
with the G-protein.
40 Indeed, homozygous mutant rats
showed LPAR1 loss-of-function phenotypes, like craniofacial
disorder (Figure 4c) and smaller size (Figure 4d), which is
comparable with the phenotype found in Lpar1 knockout
mice.
41 However, we also observed significant differences in
Figure 3 MC4R
K314X fails to localize to the plasma membrane in vitro.( a) Schematic overview of MC4R in the rat. Red indicates the location of the
ENU-induced premature translational stop. Gray indicates two isoleucine residues that were shown previously to be essential for membrane
localization.
35 (b) In vitro protein localization assays in transfected COS cells reveal plasma membrane localization for wild-type MC4R, but not for
the mutated version of MC4R. Membrane localization was detected using N-terminally HA-tagged fusion constructs and extracellular availability of
the HA tag in intact cells. (c) Both wild-type and mutant fusion proteins can be detected in fixed and permeablized COS cells, indicating that the
mutant fusion protein is expressed, but fails to properly insert into the plasma membrane.
Figure 4 Lpar1
M318R/M318R rats show a loss-of-function phenotype. (a) Schematic overview of LPAR1 in the rat. Red indicates the mutated residue,
which is located in the 8th helix and gray indicates the NPxxY motif. (b) In silico analyses of the effect of the mutation in Lpar1. The substitution of
methionine by arginine is likely to cause a severe disruption of the hydrophobic interface between helix 1, 2 and 7. This is mainly due to the fact that
arginine is significantly bigger than methionine, therefore forcing a disruption of the local structure. The fact that a hydrophobic residue is
substituted for a highly hydrophilic residue types only adds to the destabilization of the interface. (c) Homozygous mutant Lpar1 rats show a
craniofacial disorder, using a measure independent of overall head size (eye-to-nose tip length/interocular distance), which was also observed in
Lpar1 knockout mice.
41 Error bars show±s.e.m. and *indicates statistical difference, Po0.01 (n¼7 each genotype). (d) Homozygous mutant rats
are smaller. Error bars show±s.e.m. and *indicates statistical difference, Po0.01 (n¼7 each genotype). (e) LPAR1
M318R is still expressed in the
plasma membrane in vitro, although at much lower levels than wild-type LPAR1. N-terminally HA-tagged wild type or mutant receptor were
transiently expressed in COS cells. Intact cells were incubated with an antibody against HA before fixing and staining the cells. (f) Cell lysates of COS
cells expressing wild type or mutant HA-tagged LPAR1 show the comparable protein levels by western blot analysis. Both an antibody against the HA
tag as well as one against human LPAR1 was used to show the expression of the fusion proteins.
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to mice, no neonatal lethality was observed in rats because
homozygous mutants were born at the expected frequencies
(29.5%±s.e.m. 8.7; n¼4) and no hematomas were ob-
served.
41 The milder phenotype in the rat could be
explained by the nature of the mutation, which is only
G protein-coupled receptor mutants in the rat
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or deleting the protein. However, species-specific differences
can also not be ruled out. To study the molecular conseq-
uences of the non-synonymous substitution, we analyzed
the membrane expression in vitro using N-terminally
HA-tagged versions of mutant and wild-type LPAR1 iso-
forms. We observed strongly reduced, yet detectable, mem-
brane incorporation as compared with wild-type LPAR1
(Figure 4e), whereas expression levels of both fusion proteins
were equal (Figure 4f). These in vitro data suggest that the
ENU-induced mutation results in a hypomorphic allele,
which could explain the mild phenotype observed in vivo.
More detailed experiments indicated that the decreased
level of in vitro membrane expression of Lpar
M318R is most
likely the result of increased spontaneous membrane
internalization, which fits with the role of the C terminus
in receptor activation and internalization (R van Boxtel, E
Cuppen, unpublished results).
Finally, this unique resource of GPCR mutants in the
rat is not only suited for studying the in vivo effect of the
mutated receptor in behavior (for example, Gpr19, Gpr85),
immunology (for example, Ilr8b, Gpr65), or metabolism
(for example, Mc4r, Npy5r), but it can also be employed
for the derivation of primary cell cultures and studying
the molecular and functional consequences of the mutation
ex vivo. Indeed, we isolated embryonic fibroblasts from
Lpar
M318R/M318R rats to study the effect of this mutation
in an in vitro system, without the necessity of creating
transgenic cell lines (R van Boxtel, E Cuppen, unpublished
results).
Discussion
Single nucleotide polymorphisms are the most common
form of human genetic variation
42 and this class of variants is
mimicked by the action of ENU that results in the introduc-
tion of random point mutations in the genome. Therefore, in
vivo mutants generated by ENU-driven target-selected muta-
genesis can be of great relevance for studying the function of
genes and gene variants with effects on human physiology
and pathology. Here, we made use of this approach to
generate mutant models for GPCRs in the rat. The strength of
this approach is that in a single experiment a wide range of
mutants can be isolated for a large set of genes of interest.
Although the genetic toolbox of the rat has very recently
expanded significantly with techniques like transposon inser-
tion mutagenesis,
8 targeted zinc-finger nucleases-mediated
knockout generation
9 and the availability of pluripotent rat
ES cells,
10,11 ENU-driven target-selected mutagenesis has
developed in the past years into a robust and highly efficient
technique. In addition, this approach has the unique
characteristic that it simultaneously can provide allelic series
of knockout and other alleles, like hypo- and hypermorphic
mutants. Also the screen described here resulted in multiple
non-synonymous mutant alleles for the same gene (Supple-
mentary Table 2). Such alleles can be highly informative for
understanding gene function and the effects of disease-
associated variants identified in human. Finally, the technique
does not depend on special (ES) cell lines and/or advanced
oocyte or embryo manipulation and the created mutants are
not ‘transgenic’ in nature, because no artificial DNA construct
Table 3 Known human disease genes
a
Gene Mutation Category
b MIM morbid description (accession)
Cx3cr1 I118K Protein stability/folding Human immunodeficiency virus type 1, susceptibility to (609423)
Coronary heart disease, susceptibility to (607339)
Macular degeneration, age-related (603075)
Drd3 S355P Unclear effect
c Tremor, hereditary essential (190300)
Schizophrenia (181500)
Fshr V488A Protein stability/folding Ovarian hyperstimulation syndrome (608115)
Twinning, dizygotic (276400)
Ovarian dysgenesis 1 (233300)
Gnrhr I93T Protein stability/folding Fertile eunuch syndrome (228300)
Hypogonadotropic hypogonadism (146110)
Gpr56 R96H Unclear effect
c Polymicrogyria, bilateral frontoparietal (606854)
Htr2a N54D Unclear effect
c Major depressive disorder (608516)
Anorexia nervosa, susceptibility to (606788)
Schizophrenia (181500)
Obsessive-compulsive disorder 1 (164230)
Alcohol dependence (103780)
Lhcgr I446N G-protein activation Leydig cell hypoplasia, type 1 (238320)
Precocious puberty, male-limited (176410)
Mc4r K314X Protein truncation Obesity (601665)
Prokr2 S364I Signal transduction Kallmann syndrome 3 (244200)
Sstr5 V226A G-protein activation Pituitary adenoma, growth hormone-secreting (102200)
aAccording to OMIM database (http://www.ncbi.nlm.nih.gov/omim/).
bThe categories are based on expert interpretation of structural information and bioinformatic predictions unless stated differently.
cStructural information was not available for these protein domains but bioinformatic analysis by both Polyphen
27 and SIFT
28 software predicted that these mutations are
likely to have damaging consequences.
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ENU mutagenesis could be the presence of background
mutations. However, this is a complication that should be
taken into account in most approaches for the generation of
mutant animals, including homologous recombination-based
techniques as it has been shown that long-term culturing of ES
cells does result in the accumulation of genetic changes.
43
Nevertheless, the presence of background mutations can
relatively easily be controlled or overcome by outcrossing
heterozygous carriers to the parental strain
44 and the use of
wild-type and heterozygote littermates as controls in pheno-
typic characterization studies.
Although the use of MMR-deficient background for
mutagenesis has greatly increased the efficiency of ENU
target-selected mutagenesis in the rat,
14 further improve-
ments to the approach can and are still being implemented.
The availability of an archive of frozen F1 rats, which we
and others
25 are currently generating can in principle be
screened almost infinitely, and will be of great benefit to the
rat research community. In addition, the availability of next
generation sequencing platforms,
45 combined with micro-
array-based genomic enrichment,
46 provides promising
avenues for further increases in the efficiency of the ENU
target-selected mutagenesis approach by rigorously scaling
of the targeted mutation discovery effort.
Taken together, we show that ENU-driven target-selected
mutagenesis is a highly effective and feasible approach for
generating a unique and expandable resource of GPCR
mutants in the rat. We established seven novel potential
genetic knockout rat models and over 40 missense mutant
lines, including amino acid changes in very conserved GPCR
motifs like the (E/D)R(Y/W) motif and the ionic pocket,
showing the specific power of random ENU mutagenesis
in vivo. Selection of the most promising models was aided
by extensive bioinformatic analysis, which will also be
instrumental for the efficient design of molecular character-
ization strategies. Notably, at least 10 mutant lines con-
cerned genes, of which polymorphisms in the human
orthologs are known to be involved in disease processes
(Table 3). Furthermore, many of the affected genes have
been associated with one or more diseases in recent gene
and genome-wide association studies, for example, Gpr85 in
a GWAS study for attention-deficit/hyperactivity disorder
(ADHD),
47 illustrating the relevance of these rat models for
studying human disease (see http://geneticassociationdb.
nih.gov, http://www.ncbi.nlm.nih.gov/gap and http://www.
genome.gov/gwastudies/). Finally, all rat models described
here will be made available to the community through the
international rat knockout consortium (www.knockoutrat.org).
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